Skip to content

Sirtex ceo insider trading

Sirtex ceo insider trading

Sirtex CEO sacked after insider trading probe. Since Mr Wong sold out, Sirtex shares have been in a downward spiral. Share this article. Sirtex chief executive Gilman Wong has been sacked following a probe into his sale of millions of dollars worth of stock ahead of a plunge in the group’s valuation. The former head of Australian liver-cancer treatment firm Sirtex Medical Ltd has pleaded guilty to insider trading, Australia's corporate regulator said on Wednesday. Former Sirtex Medical chief executive Gilman Wong could face up to 10 years in jail after pleading guilty to insider trading. Mr Wong pleaded guilty at Sydney's Downing Central Local Court in Sydney on Tuesday to one charge of insider trading and has been committed to the Sydney District Court for sentencing, the Australian Securities and Investments Commission said on Wednesday. Mr Gilman Edwin Wong, the former Chief Executive Officer and director of Sirtex Medical Limited, appeared yesterday at the Downing Central Local Court in Sydney charged with one count of insider trading under the Corporations Act, Australian regulator ASIC informed earlier today.

Gilman Edwin Wong, the former CEO of Australian cancer therapy biotech Sirtex Medical Limited, has been charged with insider trading. Corporate regulator ASIC alleges that Wong was in possession of inside information, concerning Sirtex’s sales, when he sold 74,698 shares in Sirtex on October 26, 2016.

Former CEO of Sirtex Medical Gilman Wong has been charged with insider trading. Brianne Makin. Mr Wong could be jailed for up to 10 years if found guilty. Former chief executive and director of Sirtex Medical, Gilman Wong is staring at a jail sentence after pleading guilty to insider trading. Former Sirtex Medical CEO Gilman Wong could face up to 10 SYDNEY (Reuters) - The former head of Australian liver-cancer treatment firm Sirtex Medical Ltd has pleaded guilty to insider trading, Australia’s corporate regulator said on Wednesday. Gilman Edwin Wong, who headed the firm from 2005 to 2017, Gilman Edwin Wong, the former CEO of Australian cancer therapy biotech Sirtex Medical Limited, has been charged with insider trading. Corporate regulator ASIC alleges that Wong was in possession of inside information, concerning Sirtex’s sales, when he sold 74,698 shares in Sirtex on October 26, 2016.

Former CEO of Sirtex Medical Gilman Wong has been charged with insider trading. Brianne Makin. Mr Wong could be jailed for up to 10 years if found guilty.

The former chief executive of cancer treatment group Sirtex, Gilman Wong, has pleaded guilty to one charge of insider trading relating to a $2.1 million share sale in 2016. Former Sirtex CEO pleads guilty to insider trading. The former CEO of Australian biotechnology company Sirtex Medical, Gilman Wong, has pleaded guilty to one charge of insider trading. Mr Wong was committed to the Sydney District Court for sentencing on a date to be fixed. The maximum penalty for an insider trading offence is 10 years' imprisonment. The former chief of cancer drug developer Sirtex has been charged by the corporate regulator with insider trading. The former chief of cancer drug developer Sirtex has been charged by the corporate regulator with insider trading. Mr Wong, of Sydney, was the former CEO of Sirtex in the period 2005 to 2017. On 26 October 2016 while in possession of inside information concerning Sirtex’s sales, Mr Wong sold 74,698 Sirtex shares. He was charged with one count of insider trading under the Corporations Act on 25 September 2018 . Sirtex CEO sacked after insider trading probe. Since Mr Wong sold out, Sirtex shares have been in a downward spiral. Share this article. Sirtex chief executive Gilman Wong has been sacked following a probe into his sale of millions of dollars worth of stock ahead of a plunge in the group’s valuation. The former head of Australian liver-cancer treatment firm Sirtex Medical Ltd has pleaded guilty to insider trading, Australia's corporate regulator said on Wednesday.

Former Sirtex CEO pleads guilty to insider trading. The former CEO and director of biotech company Sirtex Medical, Gilman Edwin Wong (pictured), has pleaded guilty to one charge of insider trading. Wong was committed to the Sydney District Court for sentencing on a date to be fixed.

The former chief executive of cancer treatment group Sirtex, Gilman Wong, has pleaded guilty to one charge of insider trading relating to a $2.1 million share sale in 2016.

The former chief of cancer drug developer Sirtex has been charged by the corporate regulator with insider trading. The former chief of cancer drug developer Sirtex has been charged by the corporate regulator with insider trading.

Within days of biotech company Sirtex Medical Limited delisting from the ASX following its takeover from China's CDH Investments for $1.9 billion, former CEO Gilman Edwin Wong has been charged with insider trading. The former CEO of Australian biotechnology company Sirtex Medical, Gilman Wong, has pleaded guilty to one charge of insider trading. Mr Wong was committed to the Sydney District Court for sentencing on a date to be fixed. The maximum penalty for an insider trading offence is 10 years' imprisonment. The former CEO of Australian biotechnology company Sirtex Medical, Gilman Wong, has pleaded guilty to one charge of insider trading. Mr Wong was committed to the Sydney District Court for sentencing on a date to be fixed. The maximum penalty for an insider trading offence is 10 years' imprisonment.

Apex Business WordPress Theme | Designed by Crafthemes